SYNTHESIZED SCIENTIFIC CONSENSUS
Meta-analysis of 14 randomized controlled trials (n=2,480) confirms semaglutide and tirzepatide significantly improve NASH resolution without worsening fibrosis (OR 2.45, 95% CI 1.82–3.30). Primary endpoint efficacy correlates with ≥10% total body weight reduction across all cohorts.
| Study & Citation | Sample Size (N) | Intervention / Dose | Primary Outcome | Evidence Quality |
|---|---|---|---|---|
| Newsome et al. (NEJM 2021) | 320 patients | Semaglutide 0.4mg daily | 59% NASH resolution vs 17% placebo (p<0.001) | High (Phase IIb RCT) |
| Loomba et al. (Lancet 2023) | 190 patients | Tirzepatide 15mg weekly | 62% resolution, fibrosis stage improvement | High (Phase II RCT) |
| Sanyal et al. (Gastroenterology 2024) | 412 patients | Dual GIP/GLP-1 co-agonist | Significant reduction in hepatic steatosis | Moderate (Multi-center) |
Precision Facet Filters
Filter instantly by Clinical Trial Phase (I-IV), Meta-analysis, Sample Size, Publication Year, or Q1 Impact.
Audit-Ready Passages
Hover over any sentence in the synthesized answer to inspect the exact sentence and page in the primary PDF.
Table Extraction
Convert disparate findings across dozens of publications into structured, exportable CSV/Excel tables.
Global Preprint Inclusion
Cross-search bioRxiv, medRxiv, and arXiv alongside established databases like PubMed and IEEE Xplore.